MSU
STLN

Mizuho Securities USA’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Mizuho Securities USA’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,000
Closed -$262K – 219
2020
Q4 		$262K Sell
25,000
-25,000
-50% -$257K 0.02% 169
2020
Q3 		$508K Buy
+50,000
New +$519K 0.04% 121

Other funds holding STLN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

Mizuho Securities USA's STLN Position: Q1 2021 in Review

Mizuho Securities USA sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2021, closing a stake of 25,000 shares — an estimated $262K sold.

Mizuho Securities USA first reported a position in STLN in Q3 2020 and held it in 2 quarters. The position peaked at $508K in Q3 2020. 50 funds tracked by Wall St. Rank hold STLN as of Q1 2021.

  • Mizuho Securities USA reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Mizuho Securities USA sold 25,000 Starling Oncology Institute, Inc. Common Stock shares in Q1 2021, an estimated $262K.
  • Mizuho Securities USA first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Mizuho Securities USA's Starling Oncology Institute, Inc. Common Stock position peaked at $508K in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2021.

Based on Mizuho Securities USA's 13F filing for Q1 2021, filed 28 Apr 2021.